Differential_response_of_malignant_human_B-cells_to_anti-IgM_immunoglobulin_(anti-mu)_and_B-cell_growth_factor:_unique_direct_cytotoxicity_of_anti-mu_on_prolymphocytic_leukemia_cells._We_examined_in_vitro_tritiated_thymidine_uptake_by_B_cells_from_seven_prolymphocytic_leukemia_(PLL),_seven_chronic_lymphocytic_leukemia_(CLL),_and_four_plasma_cell_leukemia_(PCL)_patients_in_response_to_culture_with_anti-human_IgM_antibody_(anti-mu)_and_B-cell_growth_factor_(BCGF)._In_contrast_to_the_stimulatory_effect_observed_in_normal_B-cell_cultures,_the_divalent_F(ab')2_anti-mu_antibody_uniquely_inhibited_the_autonomous_proliferation_and_induced_marked_cytotoxicity_in_six_of_seven_PLL_cell_cultures_independent_of_complement_or_Fc-receptor-mediated_mechanisms._There_was_neither_stimulation_or_inhibition_of_the_slgM+_CLL_or_the_slgM-_PCL_cells._The_inhibitory_effect_on_the_PLL_cells_was_observed_at_an_anti-mu_concentration_below_the_stimulatory_threshold_for_normal_B_cells._Significant_impairment_of_trypan_blue_exclusion_was_delayed_until_48_hours,_with_morphological_cellular_changes_suggestive_of_a_programmed_cell_death_mechanism_or_apoptosis._The_cytotoxicity_was_independent_of_the_slgM-staining_intensity_or_the_autonomous_and_BCGF-augmented_DNA_synthetic_activity_of_the_PLL_cells_and_was_similar_in_patients_with_de_novo_PLL_or_with_prolymphocytic_transformation_of_CLL._Cells_from_a_PLL_patient_were_separated_by_elutriation_into_two_fractions,_a_BCGF-unresponsive_large_"transformed"_cell_fraction_with_marked_autonomous_DNA_synthesis_and_a_smaller_lymphoid_cell_subset_with_low_3H-thymidine_uptake_that_could_be_augmented_by_BCGF._Both_fractions_were_equally_susceptible_to_the_cytotoxic_effect_of_anti-mu._These_data_suggest_that_certain_slgM-bearing_malignant_B_cells_are_susceptible_to_anti-mu-triggered_cytotoxicity._They_may_represent_the_malignant_counterpart_of_a_"tolerogenic"_normal_B-cell_subset,_and_the_unique_direct_cytotoxicity_of_anti-mu_may_provide_a_therapeutic_strategy_specifically_for_PLL.